CR9904A - Compuestos que tienen actividad en el receptor M1 y sus usos en medicina - Google Patents

Compuestos que tienen actividad en el receptor M1 y sus usos en medicina

Info

Publication number
CR9904A
CR9904A CR9904A CR9904A CR9904A CR 9904 A CR9904 A CR 9904A CR 9904 A CR9904 A CR 9904A CR 9904 A CR9904 A CR 9904A CR 9904 A CR9904 A CR 9904A
Authority
CR
Costa Rica
Prior art keywords
compounds
alkyl
fluorine atoms
substituted
receptor
Prior art date
Application number
CR9904A
Other languages
English (en)
Inventor
Brian Budzik
David Gwyn Cooper
Ian Thomson Forbes
Vincenzo Garzya
Jian Jin
Dongchuan Shi
Paul William Smith
Graham Walker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0519950.0A external-priority patent/GB0519950D0/en
Priority claimed from GB0602040A external-priority patent/GB0602040D0/en
Application filed filed Critical
Publication of CR9904A publication Critical patent/CR9904A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Se proporcionan compuestos de formula (I), sales y solvatos, donde R4 es fluor, R5 se selecciona entre hidrogeno, halogeno, ciano, alquilo C1-6, alquilo C1-6 sustituido con uno o mas atomos de fluor, alcoxi C1-6 sustituido con uno o mas atomos de fluor; y R6 se selecciona entre halogeno, ciano, alquilo c1-6, alquilo c1-6 sustituido con uno o mas atomos de fluor, cicloalquilo C3-6, cicloalquilo C3-6 sustituido con uno o mas atomos de fluor, alcoxi C1-6 y alcoxi C1-6 sustituido con uno o mas atomos de fluor, y Q es hidrogeno o alquilo C1-6. Se espera que los compuestos sean utiles para terapia, por ejemplo en el tratamiento de trastornos psicoticos y alteraciones cognitivas.
CR9904A 2005-09-30 2008-04-18 Compuestos que tienen actividad en el receptor M1 y sus usos en medicina CR9904A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0519950.0A GB0519950D0 (en) 2005-09-30 2005-09-30 Compounds
GB0602040A GB0602040D0 (en) 2006-02-01 2006-02-01 Compounds

Publications (1)

Publication Number Publication Date
CR9904A true CR9904A (es) 2008-07-29

Family

ID=37598231

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9904A CR9904A (es) 2005-09-30 2008-04-18 Compuestos que tienen actividad en el receptor M1 y sus usos en medicina

Country Status (24)

Country Link
US (2) US8283364B2 (es)
EP (1) EP1943230B1 (es)
JP (1) JP5209480B2 (es)
KR (2) KR101374458B1 (es)
CN (1) CN101321736B (es)
AR (1) AR056103A1 (es)
AT (1) ATE492537T1 (es)
AU (1) AU2006296369B2 (es)
BR (1) BRPI0616609A2 (es)
CA (1) CA2624504C (es)
CR (1) CR9904A (es)
DE (1) DE602006019119D1 (es)
EA (1) EA016286B1 (es)
IL (1) IL190219A (es)
JO (1) JO2634B1 (es)
MA (1) MA29849B1 (es)
MY (1) MY148504A (es)
NO (1) NO20081945L (es)
NZ (1) NZ566508A (es)
PE (1) PE20070490A1 (es)
TW (1) TWI389905B (es)
UA (1) UA101299C2 (es)
WO (1) WO2007036715A2 (es)
ZA (1) ZA200802167B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007036711A1 (en) 2005-09-30 2007-04-05 Glaxo Group Limited BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR
WO2007036718A2 (en) 2005-09-30 2007-04-05 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
US8283364B2 (en) 2005-09-30 2012-10-09 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
US7766829B2 (en) * 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0706165D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
WO2009124882A1 (en) * 2008-04-09 2009-10-15 H. Lundbeck A/S Novel piperidinyl-1,3-dihydro-benzoimidazol-2-ones as m1 agonists
GB0817982D0 (en) 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
WO2016073294A1 (en) * 2014-11-03 2016-05-12 William Beaumont Hospital Method for treating underactive bladder syndrome
KR20170141769A (ko) * 2015-04-29 2017-12-26 얀센 파마슈티카 엔.브이. 인돌론 화합물 및 ampa 수용체 조절제로서의 이의 용도
ES2865330T3 (es) 2015-04-29 2021-10-15 Janssen Pharmaceutica Nv Azabenzimidazoles y su uso como moduladores del receptor AMPA
CA2996717A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
CN107673994A (zh) * 2017-04-27 2018-02-09 联化科技股份有限公司 一种芳基甲烷类化合物的制备方法
CN107739342B (zh) * 2017-11-29 2020-01-10 华南理工大学 一种一步合成5-二芳氨基苯并咪唑酮衍生物的方法
CN117049938B (zh) * 2023-06-20 2024-06-14 山东轩德医药科技有限公司 一种6-溴-2,3-二氟甲苯的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161645A (en) * 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3989707A (en) * 1974-06-21 1976-11-02 Janssen Pharmaceutica N.V. Benzimidazolinone derivatives
US4292321A (en) * 1979-05-24 1981-09-29 Warner-Lambert Company 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof
DE3124366A1 (de) * 1981-06-20 1982-12-30 Hoechst Ag, 6000 Frankfurt N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
DE4040300A1 (de) 1990-12-17 1992-07-02 Leifeld Gmbh & Co Drueckmaschine mit wenigstens einem rollenhalter
JP3916093B2 (ja) * 1993-09-17 2007-05-16 杏林製薬株式会社 光学活性イミダゾリジノン誘導体とその製造方法
JP2002515008A (ja) * 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
AU7478396A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine agonists
US5718912A (en) * 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6465484B1 (en) * 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2307999A (en) * 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
US6699880B1 (en) 1999-10-13 2004-03-02 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
WO2001057019A1 (en) * 2000-02-01 2001-08-09 Cor Therapeutics, Inc. INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa
EP1385518B1 (en) * 2001-04-18 2008-08-06 Euro-Celtique S.A. Benzimidazolone compounds
JPWO2002085890A1 (ja) * 2001-04-20 2004-08-12 萬有製薬株式会社 ベンズイミダゾロン誘導体
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
BR0213611A (pt) * 2001-10-02 2005-12-20 Acadia Pharm Inc Composto, composição farmacêutica, seus usos, método para aumentar a atividade de um receptor colinérgico, métodos para tratamento ou prevenção de distúrbio mental, dor, pressão intraocular aumentada e progressão ou formação de placas amilóides
US6951849B2 (en) * 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
CA2465328C (en) * 2001-11-01 2011-06-14 Michael Francis Gross Piperidines
JP4056977B2 (ja) 2002-03-29 2008-03-05 田辺三菱製薬株式会社 睡眠障害治療薬
EP1515722A4 (en) 2002-06-17 2006-06-21 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
US7645771B2 (en) 2002-12-13 2010-01-12 Smithkline Beecham Corp. CCR5 antagonists as therapeutic agents
JP2005102133A (ja) 2003-04-28 2005-04-14 Ricoh Co Ltd 画像形成装置及び宛先情報参照方法
WO2005009996A1 (en) * 2003-07-23 2005-02-03 Wyeth Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands
UA86204C2 (uk) * 2003-09-03 2009-04-10 Пфайзер Инк. Сполуки бензімідазолону, які мають 5-нт4 рецепторну агоністичну активність
ES2318556T3 (es) * 2004-11-02 2009-05-01 Pfizer, Inc. Derivados de sulfonil bencimidazol.
US7300947B2 (en) * 2005-07-13 2007-11-27 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
WO2007036711A1 (en) 2005-09-30 2007-04-05 Glaxo Group Limited BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR
US8283364B2 (en) 2005-09-30 2012-10-09 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
WO2007036718A2 (en) 2005-09-30 2007-04-05 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
CA2662333C (en) 2006-09-08 2013-12-31 The Gillette Company Toothbrush with multiple bristle states
GB0706190D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706168D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706187D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706167D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706189D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706188D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706173D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
ZA200802167B (en) 2009-08-26
DE602006019119D1 (de) 2011-02-03
US8283364B2 (en) 2012-10-09
US8481566B2 (en) 2013-07-09
AR056103A1 (es) 2007-09-19
JP5209480B2 (ja) 2013-06-12
KR20130091791A (ko) 2013-08-19
WO2007036715A2 (en) 2007-04-05
AU2006296369B2 (en) 2012-12-20
NZ566508A (en) 2011-07-29
TW200806657A (en) 2008-02-01
KR20080049090A (ko) 2008-06-03
EP1943230A2 (en) 2008-07-16
NO20081945L (no) 2008-06-04
EA016286B1 (ru) 2012-03-30
IL190219A0 (en) 2008-11-03
IL190219A (en) 2012-10-31
US20080058378A1 (en) 2008-03-06
CA2624504C (en) 2014-07-08
CN101321736B (zh) 2012-04-04
JO2634B1 (en) 2012-06-17
MY148504A (en) 2013-04-30
US20080255195A1 (en) 2008-10-16
AU2006296369A1 (en) 2007-04-05
JP2009512635A (ja) 2009-03-26
EA200801001A1 (ru) 2008-08-29
ATE492537T1 (de) 2011-01-15
MA29849B1 (fr) 2008-10-03
BRPI0616609A2 (pt) 2011-06-28
CA2624504A1 (en) 2007-04-05
PE20070490A1 (es) 2007-05-30
CN101321736A (zh) 2008-12-10
UA101299C2 (uk) 2013-03-25
EP1943230B1 (en) 2010-12-22
TWI389905B (zh) 2013-03-21
KR101374458B1 (ko) 2014-03-17
WO2007036715A3 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
CR9904A (es) Compuestos que tienen actividad en el receptor M1 y sus usos en medicina
CR10314A (es) Compuestos que tienen actividad en el receptor m 1 y sus usos en medicina
CL2020000367A1 (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
ECSP045315A (es) MIMÉTICOS DE GlucocorticoidES, PROCEDIMIENTOS PARA SU PREPARACIÓN, COMPOSICIONES FARMACÉUTICAS Y USOS DE LOS MISMOS
UY28526A1 (es) Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
CY1108451T1 (el) Παραγωγα τριαζολυλοτροπανιου ως ρυθμιστες ccr5
SV2008002828A (es) Agentes para prevenir y tratar trastornos que involucran la modulacion de los receptores ryr ref. 19240-619-sv1
ECSP099728A (es) Compuestos amino-heterocíclicos
AR073920A1 (es) Derivados urea de nortropanos sustituidos, medicamentos que contienen dichos compuestos , su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa y proceso para su preparacion.
CL2007002450A1 (es) Forma polimorfica i del enantiomero levogiro o dextrogiro de modafinilo; su procedimiento de preparacion; y composicion farmaceutica que los comprende (divisional solicitud 2693-03).
CR9881A (es) Polimorfos de la sal benzoato de 2-[[6-[(3r)-3amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y metodos de uso para los mismos
AR071385A1 (es) Compuestos de 2-imino-3-metil pirrolopirimidinona sustituida con tiofenilo,composiciones farmaceuticas que los contienen,y uso de los mismos para el tratamiento de patologias asociadas con la proteina beta amiloide,tales como alzheimer y otros formas de demencia.
AR036608A1 (es) Derivados de imidazol, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de un medicamento para el tratamiento de la obesidad
SV2005002099A (es) " nuevos compuestos " ref. pc 32096a
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
NO20072005L (no) Nye heterocykliske amider
WO2007036718A3 (en) Compounds which have activity at m1 receptor and their uses in medicine
CR9155A (es) PIRAZOLO (3,4-b) PIRIDINAS E INDAZOLES TERAPEUTICOS
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
BR0307903A (pt) derivados de arilsulfona
ECSP088602A (es) Compuestos con efectos medicinales debido a la interacción con el receptor de glucocorticoides
PE20060632A1 (es) Derivados de arilsulfonilestilbeno como antagonistas de los receptores 5-ht2a
CL2004000730A1 (es) Compuestos derivados de 4-[2-(fenilsulfanil sustituido)fenil]-1,2,3,6-tetrahidropiridina; composicion farmaceutica que los contiene; y su uso para el tratamiento de trastornos afectivos, tales como la depresion, trastornos de ansiedad, de ansiedad so
AR085276A1 (es) Antagonistas de p2x7r y su uso